CF_struct · High-Resolution X-ray Structures of Full-Length Cystic Fibrosis Transmembrane Conductance Regulator
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2016-11-16 → 2018-11-15
- EU contribution
- €175,866
- Participants
- 1
- Scheme
- MSCA-IF-EF-ST
Lines connect the coordinator with its partners.
Results in brief
High-Resolution X-ray Structures of Full-Length Cystic Fibrosis Transmembrane Conductance Regulator
The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), the protein implicated in cystic fibrosis (CF), has approximately 2,000 single mutations that cause dysfunction of the protein. Defective CFTR causes a thickening of mucus leading to infections, lowered quality of life and untimely death. Ireland, the country where these actions took place, has the highest CF birth rate. Vertex Pharmaceuticals created 3 drugs that restore activity of impaired CFTR, however these medications are expensive: Kalydeco, cost $300,000 a year per patient, a large sum of money for sick and vulnerable patients. The objectives of these actions were as follows: (1) obtain pure, active CFTR and screen for conditions that generate high-resolution crystals (2) solve the high-resolution X-ray crystal structure of CFTR in absence and presence of CF medications (3) use structure-based drug design computer programs to develop medications that increase binding specificity, improve drug efficacy and decrease financial hardships. These results have the potential to positively impact the global economy by reducing CF costs, extend life expectancy, improve quality of life and lessen the burdens placed on their caretakers. At the start of these actions, no structures existed for CFTR and we focused on X-ray crystallography. High-resolution crystal structures would give insights into the mode of action for CFTR while yielding clinically relevant details of the CFTR-drug interactions. Despite our exhaustive efforts to produce protein and the screening of tens of thousands of different crystallization conditions, CFTR remains resistant to crystal formation. Regrettably, we were not successful in the crystallization of CFTR. Cryogenic electron microscopy (CryoEM), is a lesser-established, alternative structural biology technique used to obtain structures. During these actions, 3 high-resolution CryoEM structures of CFTR were published by Jue Chen’s group from Rockefeller University, USA, yielding information on its mode of activation. Additionally, the group of John Riordan from University North Carolina at Chapel Hill, USA, our collaborator on this project, published 2 low-resolution CryoEM structures of CFTR during these actions
Data: CORDIS, © European Union
Project objective
This proposal seeks to solve the high-resolution X-ray crystal structure of full-length Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), an anion channel which regulates chloride ion concentration at the lumen-exposed surface of epithelial cells. Mutations of the CFTR gene cause cystic fibrosis (CF), a lethal disease which results in bowel obstruction, lung disease and premature death. CFTR is an ATPase and a member of the ATP-Binding Cassette (ABC) transporter family of proteins which has an allosteric Regulatory (R) domain not found in other ABC transporters. From the structure of CFTR, its mode of action will be revealed, focusing on the two sites of ATP hydrolysis and key residues for channel gating. CFTR will be crystallized alone and in the presence of the pharmacological agent Kalydeco, a small molecule from Vertex Pharmaceuticals that is used for the treatment of CF and reduces CF symptoms. The initial high-resolution X-ray crystal structure is a foundation from which personalized drug design work can begin. Therefore, the Kalydeco-CFTR complex structure will be used for ligand optimization of Kalydeco, an iterative process which will improve Kalydeco’s specificity and pharmacokinetics. The latest technology, including in meso in situ serial crystallography and X-ray free electron lasers for serial femtosecond crystallography will be used as well as traditional synchrotron X-ray sources. These Actions use an interdisciplinary mix of crystallography, chemistry, biochemistry, biophysics and computational structural determination programs. The work will take place in Ireland in the lab of Dr. Martin Caffrey at Trinity College Dublin, a distinguished researcher in the field of membrane structural and functional biology. The prestigious Marie Skłodowska-Curie fellowship will enable the candidate to actualize many objectives outlined in her career development plan in order to become an independent researcher.
Original text from CORDIS.
Participants
- THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN · DublinCoordinatorIreland
Links
- View on CORDIS
- DOI: 10.3030/704848
- https://fetics411899018.wordpress.com/probe-european-researchers-night-2018/
Data: CORDIS, © European Union
